Minnesota Devicemaker Hit for Procedural Issues

July 16, 2018

The FDA issued Summit Medical a Form 483, citing issues with CAPA and incoming product acceptance procedures as well as process validation shortcomings.

The Eagan, Minnesota-based device manufacturer’s facility was inspected in late February. The agency found that the molding process used for numerous ventilation tube models was not adequately validated. The process was inadequate because no there was no product that met the requirements under the firm’s parameters.

The firm also failed to adequately establish CAPA procedures. The firm initiated corrective actions after receiving a previous Form 483, completing mold qualifications for ventilation tubes, and subsequently closed the CAPA after verifying effectiveness. However, the mold qualifications for certain part numbers contained results that failed to meet the requirements set forth by their engineering drawings, yet were deemed acceptable.

View today's stories